Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients
December 13, 2021 07:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies,...
Cullinan Oncology to Participate in the Evercore ISI 4th Annual HealthconX Conference
November 22, 2021 12:37 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies,...
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 09, 2021 06:45 ET
|
Cullinan Oncology, Inc.
Cullinan Pearl clinical update, including data from patients enrolled in the Phase 2a expansion 100 mg BID cohort, planned for fourth quarter 2021 Cullinan MICA and Cullinan Florentine programs to...
Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer
October 18, 2021 07:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan” or “the Company”), a biopharmaceutical company focused on developing a diversified pipeline of...
Cullinan Oncology to Participate in Upcoming Investor Conferences
September 08, 2021 16:01 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced its participation in the following upcoming investor conferences: Morgan...
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 10, 2021 06:30 ET
|
Cullinan Oncology, Inc.
Follow-up Cullinan Pearl data from Phase 1 portion of ongoing trial showed increased disease control rate (DCR) of 92% in the 100mg dose cohort IND clearance of two immuno-oncology pipeline...
Cullinan Oncology to Participate in the 41st Annual Canaccord Genuity Growth Conference
August 05, 2021 16:05 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) announced today that it will be participating in the 41st Annual Canaccord Genuity Growth...
Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors
June 29, 2021 08:00 ET
|
Cullinan Oncology, Inc.
CLN-619 will be the first MICA/B-targeted antibody to enter human clinical trialsCullinan will initiate a FIH trial in 3Q21, including a dose escalation cohort followed by dose expansion cohorts as a...
Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML
June 07, 2021 08:30 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today...
Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients
June 04, 2021 09:00 ET
|
Cullinan Oncology, Inc.
CLN-081 Continues to Demonstrate Acceptable Overall Safety and Tolerability, With Encouraging GI Toxicity ProfileAs of the Data Cutoff, No Grade 3 TRAE Diarrhea at Doses Below 150mg BID; No Grade 3...